These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21535891)

  • 21. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification.
    Ooft ML; van Ipenburg J; van Loo R; de Jong R; Moelans C; Braunius W; de Bree R; van Diest P; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
    J Clin Pathol; 2018 Apr; 71(4):351-359. PubMed ID: 28893862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a non-invasive method, multiplex methylation specific PCR (MMSP), for early diagnosis of nasopharyngeal carcinoma.
    Zhang Z; Sun D; Hutajulu SH; Nawaz I; Nguyen Van D; Huang G; Haryana SM; Middeldorp JM; Ernberg I; Hu LF
    PLoS One; 2012; 7(11):e45908. PubMed ID: 23144779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma.
    Wong TS; Kwong DL; Sham JS; Wei WI; Kwong YL; Yuen AP
    Clin Cancer Res; 2004 Apr; 10(7):2401-6. PubMed ID: 15073117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
    Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
    Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma.
    Ye M; Huang T; Ni C; Yang P; Chen S
    EBioMedicine; 2017 Apr; 18():32-40. PubMed ID: 28396012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.
    Chang C; Middeldorp J; Yu KJ; Juwana H; Hsu WL; Lou PJ; Wang CP; Chen JY; Liu MY; Pfeiffer RM; Chen CJ; Hildesheim A
    J Med Virol; 2013 Mar; 85(3):524-9. PubMed ID: 23280934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
    Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
    Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
    Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
    Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
    J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
    Chan KC; Hung EC; Woo JK; Chan PK; Leung SF; Lai FP; Cheng AS; Yeung SW; Chan YW; Tsui TK; Kwok JS; King AD; Chan AT; van Hasselt AC; Lo YM
    Cancer; 2013 May; 119(10):1838-44. PubMed ID: 23436393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.